EcoDrugPlus

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSHBUG00000005134
Gene Symbol: HTR7
3 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSHBUG00000007247
Gene Symbol: LOC102310932
3 Cross references
321 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSHBUG00000015667
Gene Symbol: LOC102305864
4 Cross references
338 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSHBUG00000004103
Gene Symbol: LOC102290055
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSHBUG00000010694
Gene Symbol: LOC102292646
3 Cross references
335 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSHBUG00000014196
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSHBUG00000022516
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSHBUG00000010340
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSHBUG00000007837
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSHBUG00000011949
Gene Symbol: ADRM1
3 Cross references
191 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSHBUG00000016163
Gene Symbol: AKT1
3 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSHBUG00000018948
Gene Symbol: ABCC1
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).